Company intelligence / Profile preview

Star IT

South San Francisco, California, United Statesstarit.ge ↗

Ownership: Private
Employees: ~75
Development stage: Phase 1

Overview

Star Therapeutics has developed a unique hub-and-spoke model for drug development, creating portfolio companies each focused on specific therapeutic areas. Its lead candidate for von Willebrand disease recently received FDA Fast Track designation. Subsidiaries like Electra Therapeutics have advanced assets into early human trials for rare immune conditions such as HLH. The company has raised over $190 million since its founding in 2018 to accelerate its pipeline of novel antibody therapies targeting high unmet needs in rare diseases.

Therapeutic areas: Rare DiseasesHematology
Modalities: Antibody therapies (best-in-class antibodies)
Industry: Biotech

Drug pipeline

1 asset

VGA039

Phase 1

Indications: Von Willebrand Disease

Beyond the preview

Go deeper on Star IT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Star IT.

Explore the full profile